Carol Giltner Gallagher - 10 Jun 2025 Form 4 Insider Report for Atara Biotherapeutics, Inc. (ATRA)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
12 Jun 2025, 20:39:40 UTC
Prior SEC filing
09 Jun 2025
Next SEC filing
05 Jun 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ John Chao, Attorney-in-Fact for Carol Gallagher

Key filing fact

Carol Giltner Gallagher filed Form 4 for Atara Biotherapeutics, Inc. (ATRA) on 12 Jun 2025.

Key facts

  • This page summarizes Carol Giltner Gallagher's Form 4 filing for Atara Biotherapeutics, Inc. (ATRA).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Accepted by SEC: 12 Jun 2025, 20:39.

Change

  • Previous filing in this sequence was filed on 09 Jun 2025.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001329959 Primary reporting owner

Gallagher Carol Giltner

Relationship
Director
Address
C/O ATARA BIOTHERAPEUTICS, INC., 1280 RANCHO CONEJO BOULEVARD, THOUSAND OAKS
Signature
/s/ John Chao, Attorney-in-Fact for Carol Gallagher
Signature date
12 Jun 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ATRA transaction

Common Stock

Award

Transaction value
$0
Shares
+7,828
Change %
+31%
Price
$0.000000
Shares after
33,012
Date
10 Jun 2025
Ownership
Direct
Footnotes
F1, F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

These restricted stock units shall vest on the earlier of June 10, 2026 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service.

Footnote F2

This amount reflects the 1:25 reverse stock split effected by the Issuer on June 20, 2024.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .